STOCK TITAN

Lisata Therapeutics (LSTA) Stock News

LSTA NASDAQ

Lisata Therapeutics, Inc. develops investigational therapies for advanced solid tumors and other serious diseases. Its principal product candidate, certepetide, is a proprietary iRGD cyclic peptide designed to activate an uptake pathway that can improve tumor targeting and penetration by co-administered or tethered anti-cancer agents.

Recurring Lisata news covers clinical and preclinical data involving certepetide, collaborations and license agreements tied to antibody-drug conjugates and other delivery technologies, development-rights changes for regional markets, financial results, business updates, and corporate matters affecting governance or capital structure.

Rhea-AI Summary

Lisata Therapeutics (LSTA) subsidiary Marea reported that MAR001 met all objectives in Part A of the Phase 2b TYDAL-TIMI 78 trial. In 235 adults, placebo-adjusted fasting triglyceride reductions were 39.1%–45.5% at Week 12 across three doses (p<0.001), sustained through Week 24. Reductions reached up to 57.2% versus placebo in participants with baseline triglycerides ≥300 mg/dL, and up to 72.2% from baseline in those with levels ≥500 mg/dL.

At 900 mg, 51.7% reached triglycerides below 150 mg/dL versus 3.4% on placebo. Remnant cholesterol fell 37.3%–40.8% versus placebo. Through 24 weeks, adverse events occurred in 69.5% versus 77.6% on placebo, with no pancreatitis, deaths or worsening of HbA1c, a blood-sugar measure. Part B is enrolling approximately 100 participants with severe hypertriglyceridemia, or very high triglycerides. Results were presented at AHA Scientific Sessions 2026 and published in The New England Journal of Medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.74%
Tags
-
Rhea-AI Summary

Lisata Therapeutics (LSTA) subsidiary Marea Therapeutics will participate in three investor conferences, beginning November 10 with the Guggenheim Healthcare Innovation Conference.

Management will present in Boston at 11:30 a.m. EST, hold one-on-one meetings at the LifeSci Growth and Innovation Summit in London on November 16, and present at the Jefferies Global Healthcare Conference London on November 17 at 8:00 a.m. GMT. Both presentations will have live webcasts and replays.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.46%
Tags
none
-
Rhea-AI Summary

Lisata Therapeutics (Nasdaq: LSTA) appointed Jeffrey Farrow to its Board of Directors as a Class III director, effective October 13, 2026. Farrow fills a newly created seat, expanding the Board from seven to eight members, and will serve on the Audit Committee. The Board determined that he is independent under Nasdaq listing rules.

Farrow currently serves as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, roles he has held since April 2023. He also serves on the boards of Clover Biopharmaceuticals and Achieve Life Sciences.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.90%
Tags
management
Rhea-AI Summary

Lisata Therapeutics (Nasdaq: LSTA) has received a U.S. method-of-use patent for certepetide to treat pancreatic cancer and other solid tumors.

U.S. Patent No. 12,751,991 expires in May 2041 and expands the drug’s intellectual property protection. It covers administering certepetide, the company’s proprietary cyclic peptide, with at least one anti-cancer agent or therapy to treat, inhibit or reduce tumor volume. Covered cancers include metastatic, refractory and drug-resistant cancers—those that have spread, resist treatment or resist drugs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
none
-
Rhea-AI Summary

Lisata Therapeutics (LSTA) subsidiary Marea Therapeutics has dosed the first patient in its Phase 2 trial of MAR002 for acromegaly. MAR002 is an investigational antibody that blocks the growth hormone receptor. The study plans to enroll approximately 72 participants across three MAR002 dose arms, after an initial 900 mg loading dose, compared with placebo. Its primary endpoint is reduction in insulin-like growth factor-1 (IGF-1) following 10 weeks of treatment. Eligible participants completing that period may enter an open-label extension trial, where treatment is known to participants and researchers.

Phase 1 results presented in June 2026 showed sustained IGF-1 suppression. Marea said the drug's pharmacokinetic properties—how it moves through the body—may enable dosing as infrequently as once every two weeks, versus daily subcutaneous injections required by the current standard of care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.29%
Tags
-
Rhea-AI Summary

Marea Therapeutics, a Lisata Therapeutics (LSTA) subsidiary, announced a November 9, 2026 presentation of Phase 2b MAR001 data.

The late-breaking session at the American Heart Association Scientific Sessions in Chicago is scheduled for 8:00 a.m. CT. The TYDAL study evaluates MAR001, an antibody targeting ANGPTL4, in adults with elevated triglycerides and remnant cholesterol concentrations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.53%
Tags
Rhea-AI Summary

Lisata Therapeutics (LSTA) announced the acquisition of clinical‑stage biotech Marea Therapeutics and a concurrent private placement expected to raise approximately $225 million in gross proceeds. The combined company will focus on developing first‑in‑class, next‑generation medicines for cardioendocrine diseases, led by Marea’s late‑stage clinical candidates MAR001/005 for severe hypertriglyceridemia (sHTG) and MAR002 for acromegaly.

The private placement consists of Series C non‑voting convertible preferred stock sold to a syndicate of leading life sciences and institutional investors, with funding projected to support operations into 2028. Lisata plans to use the net proceeds primarily to complete an ongoing Phase 2b trial of MAR001/005 in sHTG and a Phase 2 trial of MAR002 in acromegaly, both expected to deliver topline data in the fourth quarter of 2027, with remaining funds for general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.37%
Tags
private placement acquisition
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.62%
Tags
-
Rhea-AI Summary

Lisata Therapeutics (Nasdaq:LSTA) announced that Kuva Labs subsidiary Kuva Acquisition has commenced a tender offer to acquire all Lisata shares. Stockholders would receive $4.00 in cash plus a non-tradeable CVR for up to $3.00 per share, subject to clinical and regulatory milestones.

The offer, unanimously recommended by Lisata’s board, expires July 10, 2026 and is expected to close in Q3 2026, subject to sufficient tenders and customary conditions. Post-closing, Lisata will be merged into Kuva, delisted from Nasdaq, and deregistered as a reporting company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.34%
Tags
none
Rhea-AI Summary

Lisata Therapeutics (Nasdaq: LSTA) agreed to be acquired by Kuva Labs for $5.00 per share in cash at closing plus one contingent value right (CVR) per share that may pay an additional $1.00 if an NDA or similar regulatory filing for certepetide is filed or accepted within seven years. The Lisata board unanimously approved and recommends tendering; the tender offer is expected to close in Q2 2026, will not include a financing condition, and will result in Lisata common stock being delisted and deregistered post-closing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.57%
Tags

FAQ

What is the current stock price of Lisata Therapeutics (LSTA)?

Lisata Therapeutics (LSTA) last closed at $1.09.

What is the market cap of Lisata Therapeutics (LSTA)?

The market cap of Lisata Therapeutics (LSTA) is approximately $11.8M.